TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05669963
Drug: lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.
Study: NCT04798612
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between
Study: NCT04798612
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between
Study: NCT05044988
Drug: HS-10342
Normalized name: sodium chloride 0.00342 MEQ/MG
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
Study: NCT05156905
Drug: Cirmtuzumab
Normalized name: Cirmtuzumab
DrugBank: Zilovertamab (DB18403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cirmtuzumab will be given in combination with docetaxel.
Study: NCT04709211
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine
Study: NCT05743179
Drug: Zoledronate
Normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
Study: NCT05575167
Drug: Zoledronate or Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion (for zoledronate) or oral digestion (for alendronate)
Study: NCT06389799
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
Study: NCT06389799
Drug: Retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor, Intravenous infusion
Study: NCT05713851
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dapagliflozin is given for 21 days vs standard of care
Study: NCT05783518
Drug: desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative anesthesia maintenance
Study: NCT05783518
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative anesthesia maintenance
Study: NCT05725837
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
Study: NCT06439914
Drug: [89Zr]Zr-DFO-emapalumab
DrugBank: Emapalumab (DB14724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
Study: NCT04634747
Drug: PVX-410
Normalized name: PVX-410 component CS1 239-247(SLFVLGLFL)
DrugBank: PVX-410 component XBP1 US184-192(YISPWILAV) (DB18559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVX-410 in combination with pembrolizumab and chemotherapy
Study: NCT04781192
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
Study: NCT04781192
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral once per day, Days 1 - 21 every 28 days
Study: NCT05913089
Drug: TQB2450 injection + Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells.
Study: NCT05913089
Drug: TQB2450 injection + Anlotinib Hydrochloride Capsule
Normalized name: terbinafine
DrugBank: Anlotinib (DB11885)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study: NCT05495828
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib, 150mg, po, qd
Study: NCT06182761
Drug: Sunvozertinib combination with Anlotinib
Normalized name: miconazole
DrugBank: Anlotinib (DB11885)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
Study: NCT04735861
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg iv. q3w, up to 2 years.
Study: NCT04735861
Drug: Bevacizumab Biosimilar IBI305
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
Study: NCT06086392
Drug: 0.1mg/kg Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block
Study: NCT06086392
Drug: 0.05mg/kg Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
Study: NCT04614246
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT04321954
Drug: LENVATINIB
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally
Study: NCT06628947
Drug: 100 μg KIO-301
Normalized name: KIO-301
DrugBank: KIO-301 (DB18465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
Study: NCT06628947
Drug: 50 μg KIO-301
Normalized name: KIO-301
DrugBank: KIO-301 (DB18465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
Study: NCT06585462
Drug: AMG 513
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 513 will be administered by SC or IV injection.
Study: NCT05753501
Drug: ABBV-101
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral:Tablet
Study: NCT05903014
Drug: n-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
Study: NCT05353010
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 5mg (1 mg \* 5 capsules)
Study: NCT05353010
Drug: IN-A001(Tegoprazan)
Normalized name: IN-A001
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
Study: NCT05353010
Drug: IN-A001(Tegoprazan) + Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
Study: NCT05191017
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide
Study: NCT00002282
Drug: Clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002282
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04641078
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg BID
Study: NCT04791878
Drug: Mesenchymal stem cells
Normalized name: Placental Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
Study: NCT05347212
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT05347212
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05779423
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody administered through intravenous infusion
Study: NCT05779423
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody administered through intravenous infusion
Study: NCT05475886
Drug: Hydroxyethyl starch 130/0.4
Normalized name: Hydroxyethyl starch 130/0.4
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05699486
Drug: Sodium chloride (placebo)
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
Study: NCT06251492
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
Study: NCT06633068
Drug: Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block
Normalized name: ACS22Q55 NERVE BLOCK KIT
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries
Study: NCT04820530
Drug: Iptacopan (LNP023)
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
Study: NCT05632328
Drug: Botensilimab
Normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: via IV, dosage per protocol, once evert 2 weeks, up to 2 years
Study: NCT05632328
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: per standard care
Study: NCT05632328
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: per standard care
Study: NCT05432804
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05432804
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04264026
Drug: 3,4-methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
Study: NCT06634108
Drug: Genistein
Normalized name: Genistein
DrugBank: Genistein (DB01645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
Study: NCT05613296
Drug: Fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
Study: NCT06606808
Drug: Risankizumab-800CW 4.5 mg
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
Study: NCT06606808
Drug: Risankizumab-800CW 15 mg
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
Study: NCT06606808
Drug: Risankizumab-800CW 25 mg
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
Study: NCT06423443
Drug: TAU
Normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual
Study: NCT06606808
Drug: Risankizumab-800CW optimal dose
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
Study: NCT05006768
Drug: Olumiant (first dose)
Normalized name: Olumiant
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet contains 4 mg Barcitinib
Study: NCT05006768
Drug: Olumiant (second dose)
Normalized name: Olumiant
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet contains 4 mg Barcitinib
Study: NCT05328336
Drug: Tislelizumab Nab paclitaxel
Normalized name: Tislelizumab
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will
Study: NCT00000693
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000693
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05149170
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
Study: NCT05488860
Drug: Triamcinolone acetonide(scar)/5-ALA(others)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For scar, the drug is triamcinolone acetonide.
Study: NCT05202262
Drug: BD MDI 320 μg
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Budesonide MDI (BD MDI), 320 μg
Study: NCT06174987
Drug: T-DXd
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
Study: NCT06586606
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04934410
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of etomidate during induction as decided by attending anesthesiologist
Study: NCT04934410
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of midazolam during induction as decided by attending anesthesiologist
Study: NCT04934410
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of sevoflurane during induction as decided by attending anesthesiologist
Study: NCT04711200
Drug: Adipose derived stromal cells intravenously injected
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×10\^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
Study: NCT05136963
Drug: Iohexol
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 milliliter of iohexol will be administrated.
Study: NCT04271332
Drug: Arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen tablet
Study: NCT04928261
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
Study: NCT06632470
Drug: Vitamin B12 Injection
Normalized name: vitamin B12 Injectable Solution
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
Study: NCT05136625
Drug: Sphenopalatine ganglion block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
Study: NCT00212173
Drug: Sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06126991
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cetirizine at 10mg once daily will be used.
Study: NCT06075225
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
Study: NCT05680233
Drug: OA-235i (4 mg)
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 participants will receive 4 mg as a single subcutaneous dose
Study: NCT05680233
Drug: OA-235i (8 mg)
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 participants will receive 8 mg as a single subcutaneous dose
Study: NCT05680233
Drug: OA-235i Dose 3
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 participants will receive a single escalating subcutaneous dose
Study: NCT05680233
Drug: OA-235i Escalating Dose 4
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 participants will receive a single escalating subcutaneous dose
Study: NCT05680233
Drug: OA-235i Escalating Dose 5
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 participants will receive a single escalating subcutaneous dose
Study: NCT05680233
Drug: OA-235i Multiple Dose
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 participants will receive a daily subcutaneous dose for 7 consecutive days
Study: NCT05893810
Drug: Mupirocin Ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
Study: NCT05674474
Drug: Vorasidenib
Normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as tablets.
Study: NCT06417411
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily use of low dose aspirin.
Study: NCT06427551
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
Study: NCT05658458
Drug: Vericiguat (Verquvo, BAY1021189)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.